

## PHARMACY POLICY STATEMENT

### North Carolina Marketplace

<b>DRUG NAME</b>	<b>Cinqair (reslizumab)</b>
BENEFIT TYPE	Medical
STATUS	Prior Authorization Required

Cinqair, approved by the FDA in 2016, is an interleukin-5 (IL-5) antagonist monoclonal antibody indicated for add-on maintenance treatment of severe asthma with an eosinophilic phenotype.

Cinqair (reslizumab) will be considered for coverage when the following criteria are met:



DATE	ACTION/DESCRIPTION
------	--------------------